Biobot Surgical developed the iSR’obot Mona Lisa, a robotic system for prostate cancer management. The Mona Lisa has MRI-ultrasound fusion capability, enabling physicians to visualize and target the region of interest. Based on custom needle plan, the robotic system controls needle positioning and depth of needle, ensuring needle entry to targeted location.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution. The robotic biopsy system not only helps physicians to detect prostate cancer in patients early, it also provides confidence to enroll patient in active surveillance program.
To date, the iSR’obot™ Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Biobot Surgical Pte Ltd is a Singapore based company that strives to be a global technology leader in minimally-invasive robotic healthcare solutions.
Brands: Biobot Surgical, iSR’obot Mona Lisa